CD8A and neoplasm: In non-tumor-bearing mice mRBC-240 induced a dose-dependent, 2–2.5 fold increase in expansion of splenic NK cells and CD8 + T cells compared with mRBC-CTRL (p = 0.0002 and p = 0.0009, respectively).